Latest Breaking News On - கிறிஸ்டியன் ரீச் - Page 1 : comparemela.com

email article Simultaneous inhibition of interleukin(IL)-17A and 17F with bimekizumab led to more rapid clearance of plaque psoriasis in significantly more patients as compared with the IL-17A inhibitor secukinumab (Cosentyx), a large randomized trial showed. After 16 weeks, 61.7% of patients treated with bimekizumab had a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) compared with 48.9% of the secukinumab arm. The 12.7% absolute difference met statistical criteria for noninferiority and superiority in favor of bimekizumab. Clearance occurred more rapidly with bimekizumab, as 71.0% of patients randomized to the IL-17A/F inhibitor had 75% or greater reduction from baseline in the PASI score at 4 weeks compared with 47.3% of the secukinumab arm.

Nordrhein westfalenUnited statesKristian reichCharles bankheadAmerican academy of dermatologyUniversity medical center hamburgPsoriasis areaSeverity indexUniversity medical center hamburg eppendorfAmerican academyNew england journalGlobal assessmentMedpage todayEngland journalEnglj medனோற்ர்ேன் வெஸ்ட்ஃபாலன்